Novel Dihydroisoquinolinone-Amide Compounds as GIPR Agonists for Treating Type 2 Diabetes Mellitus and Obesity

Provided herein are novel dihydroisoquinolinone-amide compounds as GIPR agonists, pharmaceutical compositions, use of such compounds in treating type 2 diabetes mellitus and obesity, and processes for preparing such compounds.

Authors

Ram W. Sabnis (ORCID: https://orcid.org/0000-0001-7289-0581)

Publication Details

Journal: ACS Medicinal Chemistry Letters
Published: 2026-04-16
DOI: https://doi.org/10.1021/acsmedchemlett.6c00175
Primary Topic: Pharmacology and Obesity Treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Novel Dihydroisoquinolinone-Amide Compounds as GIPR Agonists for Treating Type 2 Diabetes Mellitus and Obesity

Ram W. Sabnis

Apr 16, 2026

ACS Medicinal Chemistry Letters

Pharmacology and Obesity Treatment

article

Novel Dihydroisoquinolinone-Amide Compounds as GIPR Agonists for Treating Type 2 Diabetes Mellitus and Obesity

Ram W. Sabnis

April 16, 2026article en

Abstract

ACS Medicinal Chemistry Letters

Zero hunger

Openalex Percentile: Top 16%

Pharmacology and Obesity Treatment

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Novel Dihydroisoquinolinone-Amide Compounds as GIPR Agonists for Treating Type 2 Diabetes Mellitus and Obesity — Ram W. Sabnis · ACS Medicinal Chemistry Letters (2026) | TGRS Research Map | TGRS